EUVIMEDEUVIMED entdecken
Multizentrische Studie

Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort

Antonia Schuler, Christoph Engel iD, Aysel Ahadova iD, Katrin van Beekum iD, Stefan Aretz iD, Guido Fechner iD, Niklas Klümper iD, Nina Nelius, Emin Gashi, Hugo Montemont iD, Deepak B Vangala iD, Diana Le Duc und 12 weitere

JCO Precision Oncology · 2026-11 · 10 (11)

DOI: 10.1200/po-26-00227 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026-11. Verfasst von Antonia Schuler und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Urologic Neoplasms. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Lynch syndrome (LS), caused by pathogenic germline variants (PGVs) in DNA mismatch repair (MMR) genes, confers increased risks of colorectal, endometrial, and extracolonic malignancies. Urothelial carcinoma (UC) contributes substantially to LS-associated morbidity and mortality. We assessed its frequency, clinical presentation, genotype-associated risk, and molecular features.

Methods

We retrospectively analyzed genetically confirmed adult LS carriers in the nationwide German Consortium for Familial Intestinal Cancer registry. UC diagnoses identified by International Classification of Diseases, 10th Revision codes C65-C68 underwent manual clinical and pathologic validation. Available tumors underwent centralized pathologic review, MMR immunohistochemistry, and microsatellite instability (MSI) testing.

Results

Among 3,274 LS carriers, 144 (4.4%) had 224 primary UCs. The median age at first UC was 55 years (range, 22-79 years), and UC was the first malignancy in 50 patients (34.7%). Of 202 tumors with known location, 114 (56.4%) arose in the upper urinary tract. Metachronous and synchronous primary UCs occurred in 23 patients (16.0%) and five patients (3.5%), respectively. MSH2 -associated PGVs were present in 111 patients (77.1%). In multivariable analysis, MSH2/EPCAM carrier status was associated with UC risk (hazard ratio, 4.43 [95% CI, 2.85 to 6.89]), whereas previous colorectal cancer and UC family history were not. Among 109 patients with diagnostic information, 26 (23.9%) presented with urinary tract–related symptoms, 20 (18.3%) were diagnosed incidentally, and 11 (10.1%) were diagnosed during urologic or oncologic surveillance. Of 31 lesions from 18 patients, 29 (93.6%) were mismatch repair–deficient (dMMR) and 30 (96.8%) were MSI-high; all patients had at least one dMMR tumor and at least one MSI-high tumor.

Conclusion

UC in LS occurs relatively early, is strongly associated with MSH2/EPCAM carrier status, and represents the first malignancy in one third of patients. These findings support prospective evaluation of genotype-adapted surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal Neoplasms, Hereditary NonpolyposisUrologic NeoplasmsHumansFemaleMiddle AgedAdultAgedRetrospective StudiesMaleYoung AdultDNA Mismatch RepairMicrosatellite InstabilityMutS Homolog 2 ProteinCohort Studies

Substanzen

MutS Homolog 2 ProteinMSH2 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
  • National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
  • Department of Integrated Oncology, Center for Integrated Oncology Bonn, University Hospital Bonn, Bonn, Germany.
  • Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
  • Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.

ORCID-Profile: Christoph Engel, Aysel Ahadova, Katrin van Beekum, Stefan Aretz, Guido Fechner, Niklas Klümper, Hugo Montemont, Deepak B Vangala, Andreas Block, Tim Ripperger, Alexander Link, Elke Holinski-Feder, Jacob Nattermann, Matthias Kloor, Robert Hüneburg

Zitieren

APA

Schuler, A., Engel, C., Ahadova, A., van Beekum, K., Aretz, S., Fechner, G., Klümper, N., Nelius, N., Gashi, E., Montemont, H., Vangala, D. B., Le Duc, D., Redler, S., Block, A., Ripperger, T., Link, A., Holinski-Feder, E., Steinke-Lange, V., Schroeder, C., …, & German Consortium for Familial Intestinal Cancer (2026). Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort. JCO Precision Oncology, 10(11). https://doi.org/10.1200/po-26-00227

Vancouver

Schuler A, Engel C, Ahadova A, van Beekum K, Aretz S, Fechner G, et al. Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort. JCO Precision Oncology. 2026;10(11). doi:10.1200/po-26-00227

BibTeX
@article{Schuler2026,
  author = {Schuler, Antonia and Engel, Christoph and Ahadova, Aysel and van Beekum, Katrin and Aretz, Stefan and Fechner, Guido and Klümper, Niklas and Nelius, Nina and Gashi, Emin and Montemont, Hugo and Vangala, Deepak B and Le Duc, Diana and Redler, Silke and Block, Andreas and Ripperger, Tim and Link, Alexander and Holinski-Feder, Elke and Steinke-Lange, Verena and Schroeder, Christopher and Siebert, Reiner and Nattermann, Jacob and Kloor, Matthias and Hüneburg, Robert and German Consortium for Familial Intestinal Cancer, German Consortium for Familial Intestinal Cancer},
  title = {Urothelial Carcinoma in Lynch Syndrome: Clinical and Molecular Insights From a Large Multicenter Cohort},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {11},
  doi = {10.1200/po-26-00227}
}
Kostenlos starten →